LYL273
Refractory Metastatic Colorectal Cancer (mCRC) and other GCC-expressing cancers
Phase 1Active, enrolling
Key Facts
Indication
Refractory Metastatic Colorectal Cancer (mCRC) and other GCC-expressing cancers
Phase
Phase 1
Status
Active, enrolling
Company
About Lyell Immunopharma
Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation CAR T-cell therapies with the goal of delivering lasting remissions or cures for patients with cancer. The company's approach combines novel CAR constructs, proprietary manufacturing protocols, and T-cell biology insights to generate more potent and persistent T cells. Its lead candidate, ronde-cel, is in pivotal trials for large B-cell lymphoma, while LYL273 is in Phase 1 for metastatic colorectal cancer, representing a significant push into solid tumors. Lyell is a fully integrated company with in-house research, development, and manufacturing capabilities.
View full company profile